Results from a study evaluating the impact of mixing different coronavirus vaccines has found that all tested combinations produced a potent immune response among participants.
With funding from the British government, the Oxford Vaccine Group has been running the Com-Cov vaccine trial to determine the degree of flexibility doctors may have in prescribing different vaccines.
Researchers looked at the efficacy of either two doses of BNT162b2/Comirnaty, from Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), two of Vaxzevria, from AstraZeneca (LSE: AZN), or one followed by the other.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze